Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide + rituximab for relapsed or refractory germinal center subtype diffuse large B-cell lymphoma
ChiCTR-OPC-16008628Phase 4Recruiting
- Sponsor
- Qilu Hospital of Shandong University
- Start
- Jun 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tucidinostat and rituximab in diffuse large B-cell lymphoma (DLBCL), sponsored by Qilu Hospital of Shandong University. Primary endpoints: Imaging tumor size and Tumor marker. Started Jun 2016; status: recruiting.
02
Drugs
tucidinostatrituximab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on ChiCTR-OPC-16008628.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OPC-16008628.